ARVN - Arvinas Inc logo

Arvinas Inc

ARVN

Arvinas Inc develops therapies that utilize protein degradation to treat various diseases. Its pipeline includes treatments for neurodegenerative diseases, cancers with specific mutations, and breast cancer, relying on innovative PROTAC technology.

โš•๏ธ Healthcare NASDAQ Listed 2018 $ USD
$1,000 invested 5 years ago โ†’$87today

Score Overview

1 Year
Score
Net Growth111.51%
Net TrendGrew
Net Income Consistencyโ€”
Rev Growth20.60%
Rev TrendGrew
Revenue Consistencyโ€”
5 Years
Score6.2
Net Growth105.08%
Net Trend60%
Net Income Consistencyโ€”
Rev Growth6x
Rev Trend60%
Revenue Consistencyโ€”
All Time
Score
Net Growth122.42%
Net Trend38%
Net Income Consistency
Rev Growth22x
Rev Trend63%
Revenue Consistency

Explore the 2021 public Archive ranking โ†’

Where Arvinas Inc has ranked, year by year

Measure
Fundamentals Window

Not enough ranking history to display a chart

This chart needs at least two years of available HDB Score rankings on 10 years of fundamentals. ARVN does not have enough ranked years in the public Archive through 2021.

More recent Archive years are available with Membership. Coverage varies by company and measure.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-10-02
$ 7.41โ€”
1 Year2025-10-02
$ 9.27-20.06%
5 Years2021-10-01
$ 85.21-91.30%
All Time2018-09-27
$ 16.05-53.83%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Reported in USD

Year
TTM$ 316M$ 9M$ 567M
2025$ 262M-$ 80M$ 685M
2024$ 263M-$ 198M$ 1.03B
2023$ 78M-$ 367M$ 1.26B
2022$ 131M-$ 271M$ 1.20B
2021$ 46M-$ 183M$ 1.50B
2020$ 21M-$ 111M$ 688M
2019$ 42M-$ 62M$ 280M
IPO2018$ 14M-$ 41M$ 187M
ARVN - Arvinas Inc logo

Arvinas Inc fundamental performance

Between 2020 and 2025, revenue grew from $ 21M to $ 262M and net income went from -$ 111M to -$ 80M. Revenue increased in 3 of those 5 years; net income in 3.

Arvinas Inc currently holds a 5-year HDB Score of 6.2 out of 10. How the HDB Score is calculated.

Membership

Explore ARVN with current data

The public Archive runs through 2021. Membership adds recent and current rankings.

  • Recent and current rankings across 3,813 companies
  • Compare companies with the latest data
  • Track your research shortlist in a portfolio

$99 / year

$149/year ยท Founding price

Continue with Membership

30-day money-back guarantee.

Explore other companies